Document is current
Any future updates will be listed below
-
Authors
Glasstetter, Logan M.
Oderinde, Tomiwa S.
Mirchandani, Mohit
Rajagopalan, Kamalnath Sankaran
Barsom, Samer H.
Thaler, Roman
Siddiqi, Sarosh
Zhu, Xiang-Yang
Tang, Hui
Jordan, Kyra L.
Saadiq, Ishran M.
van Wijnen, Andre J.
Eirin, Alfonso
Lerman, Lilach O. https://orcid.org/0000-0002-3271-3887
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (DK120292, DK122734, DK129240)
National Institute on Aging (AG062104)
Regenerative Medicine Minnesota (RMM-091620-DS-004)
National Heart, Lung, and Blood Institute (HL158691)
- License Information
-
More Information
Article History
Received: 16 June 2022
Accepted: 9 May 2023
First Online: 25 May 2023
Declarations
:
: The study was approved by the Mayo Clinic Institutional Review Board (IRB) on August 15, 2018 under the title “Mesenchymal Stem Cell Senescence in Obesity” (Approval Number: 18-005076). This study adheres to the Declaration of Helsinki, and informed written consent was obtained from human participants. Animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the Mayo Clinic on January 13, 2015 under the title “MSC-derived extracellular microvesicles in metabolic syndrome and renovascular disease” (Approval Number: A65014-15).
: Not applicable.
: Lilach O. Lerman is an advisor to AstraZeneca, Cure Spec, Beren Therapeutics, Ribocure Pharmaceuticals, and Butterfly Sciences. The remaining authors declare no conflicts of interest.
